Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + docetaxel + doxorubicin (Sarcoma Alliance for Research through Collaboration)
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
gemcitabine + docetaxel + doxorubicin is a combination chemotherapy regimen evaluated by the Sarcoma Alliance for Research through Collaboration (SARC) for the adjuvant treatment of high-risk uterine leiomyosarcoma (uLMS). The regimen, specifically studied in the SARC005 Phase II clinical trial, involves the sequential administration of gemcitabine and docetaxel followed by doxorubicin after complete surgical resection of the primary tumor. Gemcitabine is a pyrimidine antimetabolite that inhibits DNA synthesis by targeting ribonucleoside reductase and incorporating into DNA. Docetaxel is a taxane that promotes microtubule assembly and inhibits depolymerization, leading to cell cycle arrest. Doxorubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, causing double-strand DNA breaks. This multi-agent approach aims to eradicate micrometastatic disease and improve progression-free survival in patients with localized but high-risk uterine leiomyosarcoma.
- Brand names
- GemzarTaxotereAdriamycin
- Other names
- Gem-Tax-DoxGemcitabine/Docetaxel/Doxorubicin
02
Targets
RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on gemcitabine + docetaxel + doxorubicin (Sarcoma Alliance for Research through Collaboration).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + docetaxel + doxorubicin (Sarcoma Alliance for Research through Collaboration).